BM8 Stock Overview
Engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BM8 passed our risk checks.
BioMarin Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$61.80 |
| 52 Week High | US$90.52 |
| 52 Week Low | US$58.16 |
| Beta | 0.31 |
| 11 Month Change | -4.63% |
| 3 Month Change | -23.10% |
| 1 Year Change | -22.92% |
| 33 Year Change | -19.28% |
| 5 Year Change | -14.24% |
| Change since IPO | 357.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| BM8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.0% | -0.2% | 0.8% |
| 1Y | -22.9% | -16.9% | 9.1% |
Return vs Industry: BM8 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: BM8 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| BM8 volatility | |
|---|---|
| BM8 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BM8 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BM8's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 3,401 | Alexander Hardy | www.biomarin.com |
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
BioMarin Pharmaceutical Inc. Fundamentals Summary
| BM8 fundamental statistics | |
|---|---|
| Market cap | €11.69b |
| Earnings (TTM) | €307.63m |
| Revenue (TTM) | €2.63b |
38.0x
P/E Ratio4.4x
P/S RatioIs BM8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BM8 income statement (TTM) | |
|---|---|
| Revenue | US$2.75b |
| Cost of Revenue | US$1.31b |
| Gross Profit | US$1.44b |
| Other Expenses | US$1.12b |
| Earnings | US$322.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.69 |
| Gross Margin | 52.35% |
| Net Profit Margin | 11.71% |
| Debt/Equity Ratio | 11.0% |
How did BM8 perform over the long term?
See historical performance and comparison